EA202192865A1 - Лечение головной боли с использованием антител к cgrp - Google Patents

Лечение головной боли с использованием антител к cgrp

Info

Publication number
EA202192865A1
EA202192865A1 EA202192865A EA202192865A EA202192865A1 EA 202192865 A1 EA202192865 A1 EA 202192865A1 EA 202192865 A EA202192865 A EA 202192865A EA 202192865 A EA202192865 A EA 202192865A EA 202192865 A1 EA202192865 A1 EA 202192865A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cgrp
headache
antibodies
treatment
migraine
Prior art date
Application number
EA202192865A
Other languages
English (en)
Inventor
Роджер К. Кэди
Джеффри Т.Л. Смит
Джозеф Хирман
Барбара Шэффлер
Лахар Мехта
Original Assignee
Х. Лундбекк А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2020/012781 external-priority patent/WO2020146527A1/en
Application filed by Х. Лундбекк А/С filed Critical Х. Лундбекк А/С
Publication of EA202192865A1 publication Critical patent/EA202192865A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Предусмотрены способы немедленного облегчения мигрени или головной боли, включающие введение антагонистического антитела к CGRP пациенту, нуждающемуся в этом. Настоящее изобретение относится к способам лечения расстройств, сопровождающихся головной болью, таких как мигрень, с использованием антител и их фрагментов (включая Fab-фрагменты), которые специфически связываются с кальцитонин-ген-связанным пептидом человека (далее в данном документе "CGRP").
EA202192865A 2019-05-02 2020-02-18 Лечение головной боли с использованием антител к cgrp EA202192865A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962842162P 2019-05-02 2019-05-02
US201962872989P 2019-07-11 2019-07-11
PCT/US2020/012781 WO2020146527A1 (en) 2019-01-08 2020-01-08 Acute treatment and rapid treatment of headache using anti-cgrp antibodies
PCT/US2020/018702 WO2020222892A1 (en) 2019-05-02 2020-02-18 Treatment of headache using anti-cgrp antibodies

Publications (1)

Publication Number Publication Date
EA202192865A1 true EA202192865A1 (ru) 2022-02-14

Family

ID=73028680

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192865A EA202192865A1 (ru) 2019-05-02 2020-02-18 Лечение головной боли с использованием антител к cgrp

Country Status (17)

Country Link
US (1) US20220251178A1 (ru)
EP (1) EP3962522A4 (ru)
JP (1) JP2022533030A (ru)
KR (1) KR20220004053A (ru)
CN (1) CN113811326A (ru)
AU (1) AU2020267107A1 (ru)
BR (1) BR112020027063A2 (ru)
CA (1) CA3133571A1 (ru)
CL (1) CL2021002866A1 (ru)
DO (1) DOP2021000215A (ru)
EA (1) EA202192865A1 (ru)
IL (1) IL287759A (ru)
JO (1) JOP20210247A1 (ru)
MA (1) MA55815A (ru)
MX (1) MX2021013426A (ru)
SG (1) SG11202110637RA (ru)
WO (1) WO2020222892A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL310885A (en) * 2021-08-27 2024-04-01 H Lundbeck As Treatment of cluster headache using anti-CGRP antibodies
KR20240058082A (ko) 2021-09-15 2024-05-03 하. 룬드벡 아크티에셀스카브 항-cgrp 항체 투약 및 스크리닝 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI646111B (zh) * 2011-05-20 2019-01-01 艾爾德生物控股有限責任公司 抗降血鈣素基因相關胜肽（ａｎｔｉ－ｃｇｒｐ）組成物及其用途
AU2012258980B8 (en) * 2011-05-20 2017-06-15 H. Lundbeck A/S Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
MX2016012188A (es) * 2014-03-21 2017-04-27 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
JOP20200116A1 (ar) * 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
EP3448427A1 (en) * 2016-04-29 2019-03-06 CureVac AG Rna encoding an antibody
KR20190066607A (ko) * 2016-09-23 2019-06-13 테바 파마슈티컬스 인터내셔널 게엠베하 불응성 편두통의 치료
JP2022516956A (ja) * 2019-01-08 2022-03-03 ハー・ルンドベック・アクチエゼルスカベット 抗ｃｇｒｐ抗体を用いた頭痛の急性治療及び迅速治療

Also Published As

Publication number Publication date
EP3962522A1 (en) 2022-03-09
AU2020267107A1 (en) 2021-10-07
IL287759A (en) 2022-01-01
BR112020027063A2 (pt) 2021-11-16
US20220251178A1 (en) 2022-08-11
MX2021013426A (es) 2021-12-10
MA55815A (fr) 2022-03-09
CL2021002866A1 (es) 2022-06-17
DOP2021000215A (es) 2021-11-21
JOP20210247A1 (ar) 2023-01-30
JP2022533030A (ja) 2022-07-21
WO2020222892A1 (en) 2020-11-05
CN113811326A (zh) 2021-12-17
CA3133571A1 (en) 2020-11-05
SG11202110637RA (en) 2021-10-28
EP3962522A4 (en) 2023-07-19
KR20220004053A (ko) 2022-01-11

Similar Documents

Publication Publication Date Title
EA202092933A1 (ru) Антитела к entpd2, виды комбинированной терапии и способы применения антител и видов комбинированной терапии
PH12021550793A1 (en) Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
MX2024002158A (es) Anticuerpos anti-ccr8 y usos de estos.
PH12021550802A1 (en) Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
PH12017502358A1 (en) Factor xi antibodies and methods of use
MA47313A (fr) Formulations sous-cutanées d'anticorps her2
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
DE69932084D1 (de) Antikörperfragmente zur lokalen Behandlung von Augenerkrankungen
MXPA06012601A (es) Anticuerpos especificos de fcy riib humanizados y metodos de uso de los mismos.
EA202190235A1 (ru) Антитела к cd33 и способы их применения
EA202091747A1 (ru) Составы антитела b7-h4
MX2022007231A (es) Anticuerpos anti-mertk y metodos de uso de los mismos.
ZA202202363B (en) Antibodies against ilt2 and use thereof
EA202192865A1 (ru) Лечение головной боли с использованием антител к cgrp
EA202090791A1 (ru) Агонистические антитела против cd40
CR20220078A (es) Anticuerpos anti-ms4a4a y métodos de uso de los mismos
EA202190647A1 (ru) Антитела к klrg1
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
PH12020552222A1 (en) Immunodominant proteins and fragments in multiple sclerosis
NZ762312A (en) Anti-pacap antibody
EA202092593A1 (ru) Белки, связывающие каннабиноидный рецептор 1-го типа (cb1), и их применение
MX2022004058A (es) Kir3dl3 es un receptor inhibidor del sistema inmunitario y usos del mismo.
MX2022002235A (es) Combinacion de urolitina con el tratamiento de inmunoterapia.
ZA202205813B (en) Trpv1 epitopes and antibodies